Recipharm increases blow fill seal capacity in Kaysersberg, France
Recipharm, the contract development and manufacturing organisation (CDMO), has announced an €18 million investment to expand its blow fill seal (BFS) capacity at its site in Kaysersberg, France
The investment will see the introduction of a new blow fill seal high speed filling and packaging line, bringing the total number of lines from seven to eight to meet growing demand for the service.
Preparations will also be made to add a further three filling lines over the coming years, more than doubling the size of the CDMO’s operations from 2,000 square metres to 4,150 square metres and increasing its blow fill seal capacity by 50 per cent. The first of the four planned filling lines will allow Recipharm to support more drug developers with the aseptic processing of sterile liquids such as eye care and ear drops into plastic containers.
Yves Buelens, General Manager at Recipharm’s Kaysersberg site, said: “We are experiencing increased demand for our blow fill seal services from markets including the US, Turkey, Australia and Canada and the new filling line will help us to meet this growing need”.
“The increased capacity will position us well for future growth and allow us to take on new projects from new customers more swiftly. With the site’s big pharma heritage, we are ideally placed to meet the highest quality and regulatory requirements and are committed to investing in the facility to ensure we can continue to deliver the best possible service.”
Recipharm serves 250+ customers globally, offering manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs and pharmaceutical product development. The Kaysersberg site, located in Alsace, France, is a sterile facility specialising in blow fill seal technology for sterile liquids. The site manufactures single dose units and has an advanced aseptic process for sterile liquid packaging applications in plastic containers.
For media enquiries, please contact Lindsay Baldry at ramarketing: firstname.lastname@example.org, + 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and its services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03